3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Terminated
1
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Sarcoma, Kaposi
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
Paclitaxel
31
Cyclophosphamide
30
Cisplatin
29
Bevacizumab
28
Carboplatin
27
Fluorouracil
24
pembrolizumab
21
Nivolumab
21
Leucovorin
20
Rituximab
19
avelumab
18
Gemcitabine
18
Docetaxel
18
Dexamethasone
18
Capecitabine
17
ALT-803
15
130-nm albumin-bound paclitaxel
14
Oxaliplatin
12
Cetuximab
12
fludarabine
11
Ipilimumab
11
venetoclax
10
atezolizumab
10
Radiosurgery
10
Radiotherapy
9
Pemetrexed
9
Omacor
9
Lenalidomide
9
Bendamustine Hydrochloride
9
yeast-CEA vaccine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
INDUSTRY
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn